PepGen reports second quarter 2022 financial results

Read more

Vaccitech reports second quarter 2022 financial results

Read more

Oxford Science Enterprises portfolio company MiroBio to be acquired by Gilead Sciences for approximately $405 million

Read more

Gilead Sciences to Acquire MiroBio

Read more

PepGen appoints Caroline Godfrey, Ph.D. to the company’s scientific advisory board

Read more

First Light strikes long-term collaboration agreement with engineering leaders IDOM

Read more

Brill powering its way to making batteries smarter with $10.5m Series A round

Read more

Oxford Science Enterprises Raises £250 Million

Read more

PQShield algorithms to be standardised as the National Institute of Standards and Technology (NIST) announces the first international Post-Quantum Cryptography standards

Read more

OMass Therapeutics appoints Dr Jon Roffey as Vice President, Head of Medicinal Chemistry

Read more

SpyBiotech appoints seasoned biotech executive Mark Leuchtenberger as Chief Executive Officer

Read more

Oxford Ionics and Infineon join forces to develop leading Trapped Ion Quantum Processors

Read more

Evolito acquires Electroflight

Read more

Oxford Quantum Circuits raises £38 million Series A to accelerate R&D and expand into Asia-Pacific

Read more

MiroBio raises $97 million Series B financing to develop checkpoint agonists for treatment of autoimmune diseases

Read more

Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

Read more

PepGen reports first quarter 2022 financial results and recent corporate developments

Read more

Nucleome Therapeutics appoints Dina Anderson as Vice President of Operations

Read more

ORCA Computing provides UK MoD with first quantum computer

Read more

ORCA Computing completes $15 million Series A funding round

Read more

EdTech Leader BibliU Raises $15M in Series B Funding

Read more

Arbutus and Vaccitech dose first patient in Phase 2a clinical trial combining therapies for the treatment of chronic hepatitis B virus

Read more

Queen’s Birthday Honours recognise service from Vice-Chancellor and Oxford colleagues

Read more

Theolytics’ £1M project with InnovateUK to develop a novel therapy for multiple myeloma patients

Read more

moa announces Series B funding

Read more

Oxford’s REF 2021 results show largest volume of world-leading research

Read more

Salience Labs Raises $11.5 Million Seed to Develop Ultra High-speed Chips Using Photonics for AI Applications

Read more

Professor Irene Tracey CBE FMedSci nominated as next Oxford Vice-Chancellor

Read more

Studies using SpyBiotech’s vaccine technology shows potential against Covid-19 and other Coronaviruses

Read more

OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases

Read more

Nucleome Therapeutics appoints Phil Boyd as Chief Financial Officer

Read more

Oxford Science Enterprises Appoints Richard Laxer, Former Chairman and CEO of GE Capital, as a Non-Executive Director

Read more

Util announces the closing of a seed round

Read more

Refeyn closes Series B funding round

Read more

OxfordVR Technology a World First Success in Automating Psychological Therapy Using Virtual Reality (VR)

Read more

Vaccitech Announces Notification of Milestone and Royalty Revenue relating to sales of Vaxzevria®

Read more

Publication in Nature by OMass Founder, Professor Dame Carol Robinson, Shows Power of Native Mass Spectrometry in Drug Discovery by Capturing GPCR Signalling in Native Membrane Environment

Read more

PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

Read more

PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development

Read more

First Light achieves world first fusion result, proving unique new target technology

Read more

New Report Highlights Oxford as the UK’s Leading University for Spinout Creation with Oxford Science Enterprises Named as Most Active Fund Focused Solely on a Single Institution 

Read more

PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology

Read more

Oxford Science Enterprises Strengthens Investment Teams with Two New Appointments

Read more

Scenic Biotech and the Barth Syndrome Foundation announce partnership to explore genetic modifiers to find tailored treatment for the complex rare disease

Read more

Vaccitech reports full-year 2021 financial results and recent corporate developments

Read more

Mixergy partners with UK’s largest online plumbing and heating merchant to offer full range of tanks nationwide

Read more

Higher Education tech leader BibliU announces Learning Enablement platform

Read more

Osler Diagnostics appoints Chris Smith as Chairman of the Board and David Berry as a Non-Executive Director

Read more

Osler Diagnostics publishes update on its breakthrough product, the Osler Origin

Read more

Blood testing start-up Osler to tap investors as it primes device launch

Read more

Can this scientist solve the world’s energy crisis?

Read more

Mind Foundry win CogX Explainable AI Award for 2022

Read more

PepGen announces approval by health Canada of CTA to begin first in human trials of PGN-EDO51 to treat Duchenne Muscular Dystrophy

Read more

Oxford Science Enterprises enters agreement with Lothbury to develop state-of-the-art R&D facilities in Oxford City Centre

Read more

Scenic Biotech Announces $31 Million Financing to Progress Pipeline of Genetic Modifiers in Cancer and Rare Diseases

Read more

Orbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologies

Read more

OMass Establishes Scientific Advisory Board of Leading Experts

Read more

OQC becomes first European quantum company on Amazon Braket

Read more

OMass’s OdyssION™ drug discovery platform makes progress in drugging the undruggable, including Gasdermin D

Read more

Wolverhampton NHS cardiologists to use new cloud technology to interpret echocardiograms

Read more

Nucleome Therapeutics appoints Nigel Clark as Chief Business Officer

Read more

First Light Fusion announces close of Series C fund raise

Read more

Nucleome Therapeutics Announces Formation of Advisory Board

Read more

Oxford Science Enterprises Strengthens Investment Teams with Two Senior Appointments

Read more

Metaboards announces Executive Chairman appointment

Read more

Refeyn announces the launch of its new TwoMP Auto mass photometer

Read more

Quantum Motion opens new lab in London to build scalable quantum computer

Read more

Opsydia Introduces Surface ID System to Complement Existing Sub-Surface Technology

Read more

AI harnessed for early identification of cardiovascular problems

Read more

First Patient Recruited for Multi-year Collaborative Primary Sclerosing Cholangitis (PSC) Study using Perspectum’s Technology

Read more

PQShield Raises $20 Million in Series A Funding to Help Fuel International Expansion

Read more

Oxford Science Enterprises Enters 2022 with Strengthened Senior Leadership Team

Read more

Harwell Campus to Provide Testbed Demonstrating Energy Storage Innovations

Read more

ONI Closes $75 Million Series B Led by ARCH Venture Partners and Casdin Capital

Read more

First Patient Dosed in Vaccitech’s Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

Read more

NHS Pilots Genetic Testing to Predict Risk of Heart Disease

Read more

Introducing: Athene Blakeman, Head of Legal

Read more

Oxford Academics Raise Record £1.4bn after University’s Covid Success

Read more

Our End of Year Newsletter 2021

Read more

Navenio Secures $12.6M Investment for Acceleration of Global Healthcare and Beyond

Read more

Ultromics: Breakthrough study shows EchoGo technology is capable of independently reading stress echocardiograms

Read more

Circadian Therapeutics makes jump to become clinical phase company

Read more

Vaccitech strengthens position as a leader in immunotherapies and vaccines with Avidea Technologies acquisition

Read more

Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV

Read more

Dow Jones Enhances Product Line with Semantic Innovation from Oxford Semantic Technologies

Read more

OxSciences Board Update: Some sad farewells and a warm welcome to our new members

Read more

OQC coming to Amazon Braket

Read more

Meltwater acquires AI spin-out from Oxford University’s Department of Computer Science to help build one of the largest knowledge graphs of public information

Read more

Ecobubl: A new Mixergy stockist and training centre

Read more

Vaccitech wins the ‘Most Significant Contribution to the Mediscience Sector Award’ by the European Mediscience Awards 2021 alongside AstraZeneca, the Jenner Institute and Oxford Biomedica!

Read more

SpyBiotech announces the appointment of Simon Jones as VP, Finance and Operations and expansion of the scientific team

Read more

Valve industry veteran, Colin Findley, joins Oxford Flow as Chief Strategy Officer

Read more

Oxford vaccine reaches two billion dose milestone

Read more

Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

Read more

Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses

Read more

Caption Health and Ultromics Partner to Put Heart Disease Detection and Management Tools in More Hands

Read more

Quantum Dice raises £2 million in pre-seed funding to revolutionise the security of encryption keys

Read more

Building a sustainable quantum future: OQC pledges carbon neutrality by 2022

Read more

Evox Therapeutics expands its exosome patent portfolio

Read more

CaRi-Heart® from Caristo: CT Coronary Perivascular Fat Assessment Can Stratify Cardiac Risk Associated With High-Risk Plaques

Read more

PepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development

Read more

Gene linked to doubling the risk of death due to COVID-19 identified using technology exclusively licensed to Nucleome Therapeutics

Read more

Navenio and HERE Technologies to Bring Increased Efficiency to Indoor Location & Mapping with Global Partnership

Read more

OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins

Read more

Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus

Read more

OQC collaborates with NQCC to boost UK quantum capability

Read more

Talking Tech Transfer: Alexis Dormandy

Read more

BibliU has received the 2021 EdTechX Scale-Up award

Read more

Wichita State University Campus of Applied Sciences and Technology Adopts BibliU Universal Learning

Read more

Six years for Oxford Flow

Read more

PQShield announces new hires to accelerate business growth

Read more

PepGen Appoints Noel Donnelly as Chief Financial Officer

Read more

Ailsa Keyser, one of Oxford Quantum Circuits brilliant quantum engineers, shortlisted for this year’s We Are Tech Women’s awards

Read more

Landmark paper highlights Evox Therapeutics’ cutting edge exosome engineering approach for enhanced surface display of biologics

Read more

Avin Bansal joins #Ultromics as the new Chief Financial Officer

Read more

First Light Fusion represents UK fusion sector at the UK Government’s Global Investment Summit

Read more

Brill Power has launched the first in a new class of ‘intelligent’ battery management systems set to revolutionise battery performance

Read more

We welcome Oran Muduroglu as Caristo Diagnostics’ Chairman

Read more

Opsydia technology advances to secure identity of melee diamonds

Read more

Ultromics announces collaboration with Janssen to develop AI for patients with amyloidosis with cardiac involvement

Read more

YASA Spin-Out Evolito to Electrify Aerospace Market With Ultra-High Performance, Low-Weight Electric Motors

Read more

Former Novartis executive Dr. Carolin Barth joins MiroBio as CEO

Read more

Peter George appointed Chairperson of OQC’s Board

Read more

Oxford University retains top spot in world rankings for sixth consecutive year

Read more

PepGen announces new additions to leadership team and Board of Directors

Read more

Genomics academic founder and CEO, Sir Peter Donnelly, awarded Royal Society Gabor medal

Read more

Introducing: Dr Ceri Morgan, Head of Late Stage Portfolio

Read more

OUR SUMMER 2021 NEWSLETTER

Read more

Meet the Academic Founder: Dr. Ross Upton, Founder & CEO, Ultromics

Read more

Ultromics raises $33M in Series B funding to help transform cardiac disease treatment

Read more

PepGen announces closing of $112.5 Million crossover financing to advance transformative therapies for neuromuscular diseases

Read more

YASA has been acquired by Mercedes-Benz AG – the acquisition will accelerate the impact of YASA’s world-leading technology, supporting adoption of electric vehicles on a global scale

Read more

Orbit Discovery Announces $7.6 Million funding to accelerate growth in peptide discovery business

Read more

Perspectum Launches New Clinical Study to Investigate Integrated Diagnostics to Enable Precision Medicine for Liver Cancer Patients

Read more

Vaccitech has entered into a Phase 2a clinical trial collaboration agreement with Arbutus Biopharma Corporation to evaluate an innovative combination of their therapeutic technologies for the treatment of patients with chronic HBV infection

Read more

OQC delivers the UK’s first Quantum Computing as-a-Service

Read more

Introducing our newest Scientist in Residence: Sarah Leonard

Read more

Ultromic’s EchoGo Predicts Cardiac-Related COVID-19 Mortality Revealed in WASE Study

Read more

UK Science Minister Amanda Solloway MP launches First Light Fusion’s maiden ‘Big Gun’ fusion campaign

Read more

Caristo Diagnostics, Navenio and Perspectum are three of the 38 winners of the NHSX AI Lab’s second wave of AI in Health and Care Awards

Read more

DNV verifies Brill Power’s new battery management system technology

Read more

Oxford University academics recognised in Queen’s Birthday Honours – including Vaccitech co-founders

Read more

Nucleome Therapeutics has published its novel 3D genome analysis method, a significant advancement in the field, in the journal Nature

Read more

ONI among the +20 organisations brought together by the Cell and Gene Therapy Catapult to accelerate technology development in cell and gene therapy manufacturing

Read more

Caristo Diagnostics’ technology can predict heart attacks nearly a decade in advance – it is now in use on Harley street and will soon be available on the NHS

Read more

PepGen Strengthens Leadership Team with SVP of Chemistry, Manufacturing & Controls and VP of Finance Appointments

Read more

Nucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its Board

Read more

ONI Welcomes Dr Tyler Ralston as Chief Technology Officer

Read more

Welcome to the portfolio Ivy Farm Technologies! Find out why Ivy Farm is the future for meat lovers, animal lovers and our planet.

Read more

First Light Fusion installs UK’s biggest two-stage hyper-velocity gas gun to advance its projectile fusion technology.

Read more

Perspectum partners in a new study in Singapore for the early detection of liver cancer using precision medicine

Read more

Vaccitech announces closing of $110.5 million initial public offering – the 1st IPO for the Oxford Science Enterprises portfolio!

Read more

Vaccitech announces pricing of initial public offering – the 1st IPO for the Oxford Science Enterprises portfolio!

Read more

Perspectum’s new study shows measurable organ impairment in Long COVID patients

Read more

Alexis Dormandy has joined the UK government’s new expert council formed to maximise UK investment offer

Read more

OUR SPRING 2021 NEWSLETTER

Read more

Ultromics CE Mark’s EchoGo Core

Read more

Oxford Endovascular Ltd raises $10m to develop its origami engineered medical device to prevent brain haemorrhage

Read more

Quantum Computing Breakthrough Shows Blueprint for Scalable Future

Read more

Perspectum research links high liver fat to increased risk of hospitalization in COVID-19 patients with obesity

Read more

Meet the Founders: Cheerag Shirodaria, CEO and Charalambos Antoniades, CSO, Caristo Diagnostics

Read more

Caristo Diagnostics announces EU approval for AI technology which can predict heart attacks years in advance

Read more

Vaccitech appoints Joseph Scheeren, PharmD, to its Board of Directors

Read more

Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

Read more

Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results

Read more

Meet Oxford’s Female Founders & CEOs – watch the recorded event!

Read more

International Women’s Day: Meet Oxford’s Female Founders

Read more

SpyBiotech announces the appointments of Dan Menichella as Non-Executive Director and Dr Norman Begg as Scientific Advisor

Read more

MoA Tech appoints Virginia Corless as CEO

Read more

Perspectum Lands Top Spot in Alantra Pharma Fast 50 Rankings

Read more

Vaccitech appoints two independent board directors

Read more

Genomics Plc completes oversubscribed $30m funding round

Read more

PepGen Announces Formation of Scientific Advisory Board

Read more

Welcome to the portfolio: T-Cypher Bio

Read more

EVOX THERAPEUTICS COMPLETES £69.2 MILLION SERIES C FINANCING

Read more

£2.5M for intelligent battery technology start up, Brill Power

Read more

SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman

Read more

OUR WINTER 2021 NEWSLETTER

Read more

Professor Jerry Chittenden joins First Light Fusion’s Advisory Board

Read more

PepGen appoints James McArthur, Ph.D., as President and Chief Executive Officer

Read more

Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman

Read more

First patient receives Vaccitech’s VTP-300 in a Phase 1b/2a clinical trial. An experimental immunotherapy for chronic HBV, a global health problem affecting over 250 million people

Read more

Introducing our first Entrepreneur in Residence from Biopharma: Damian Crowther

Read more

John McHutchison joins the board of Evox Therapeutics

Read more

Perspectum’s CoverScan MD approved by the UK’s MHRA – the world’s first integrated imaging service capable of mapping the impact of COVID-19 on the body

Read more

Ex-Centrica and BP boss Iain Conn joins Oxford Flow board

Read more

OQC lab takes delivery of first Proteox worldwide – a significant milestone to building a quantum-powered future

Read more

OQC state-of-the-art quantum laboratory opens

Read more

Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies

Read more

Ultromics’ first-of-a-kind AI solution to help clinicians diagnose coronary artery disease from echiocardiograms in a matter of minutes approved by the FDA

Read more

Bodle Technologies Secures Series A Funding Extension

Read more

Perspectum issued CPT® Codes for LiverMultiScan® by the American Medical Association to help Drs diagnose and treat liver disease

Read more

Clean nuclear: Oxford start-up 10 years ahead of government targets in race to build fusion plant

Read more

LifeArc co-leads £6 million funding in DJS Antibodies

Read more

MERRY CHRISTMAS FROM ALL THE TEAM

Read more

Meet the Founder: Sumi Biswas, CEO of SpyBiotech

Read more

PepGen raises $45M in Series A funding, led by RA Capital

Read more

HEXR launches smartphone fitting app: Bespoke, 3D printed helmets now accessible to millions

Read more

Software Ate the World, and Soon It Will Write Itself – Wall Street Journal article by Diffblue

Read more

Counterfeit drugs and illegitimate vaccines, both costly and deadly, could be a thing of the past with new breakthrough testing technology from Proxisense and Oxford University

Read more

Refeyn Closes Series A Funding Round, led by Northpond Ventures

Read more

The Backstory: Vaccitech and its role in co-inventing the Oxford COVID-19 vaccine

Read more

BREAKTHROUGH FOR OXFORD’S COVID VACCINE, CO-INVENTED BY VACCITECH

Read more

Evox Therapeutics launch strategic collaboration with Oxford University to accelerate development of exosome therapies for rare diseases

Read more

Mind Foundry raises an additional $13.6 million in Series A funding led by Aioi Nissay Dowa Insurance

Read more

OUR AUTUMN 2020 NEWSLETTER

Read more

The Backstory: Base Genomics and their mission to defeat cancer through early diagnosis

Read more

Oxford Science Enterprises announces the sale of Base Genomics to Exact Sciences

Read more

Vaccitech expands management team with hires including CMO and CFO

Read more

Notice of Annual General Meeting

Read more

Fusion energy can be the most cost competitive source of baseload power, at the same level as renewables

Read more

Oxford Science Enterprises appoints Alexis Dormandy as CEO

Read more

Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech

Read more

3 portfolio companies win the NHSX AI in Healthcare Award

Read more

SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

Read more

Biocentury feature: Oxford Science Enterprises leverages foundational deal with Oxford to build its life sciences portfolio

Read more

Celebrating five years of Oxford Science Enterprises and Oxford’s history of innovation

Read more

Meet the Founder: Ilana Wisby, CEO of Oxford Quantum Circuits

Read more

The genome only makes sense in 3D, by Lachlan Mackinnon

Read more

Orca Computing raises £2.9m in pre-seed funding for photonics quantum computer

Read more

Positive Phase 1 readout of Dr Sarah Gilbert covid vaccine

Read more

Cybersecurity in the age of quantum: Our investment in PQShield

Read more

Evox announces landmark partnerships with pharma giants Takeda and Eli Lilly

Read more

Welcome to the portfolio, Base Genomics!

Read more

A royal launch of our Grassroots incubator space!

Read more

Uciane Scarlett, our Life Sciences principal, on an inclusive biotech sector

Read more

Vaccitech CEO Bill Enright on the Oxford Covid-19 vaccine

Read more

Ultromics featured in the Wall Street Journal

Read more

Introducing the Scientist in Residence

Read more

Quantum Motion raises £8m in an oversubscribed Series A led by Inkef Capital

Read more

Vaccitech partners with the University of Oxford and AstraZeneca to develop a Covid-19 vaccine

Read more

Huma Health (formerly Medopad) acquires Biobeats to develop their mental health capabilities

Read more

Niantic acquires 6D.ai to develop their augmented reality platform

Read more

Congratulations OMass! Team raises £27.5m in additional Series A funding

Read more

Patrick Pichette to step down from Oxford Science Enterprises board, Chris Chambers announced as new chair

Read more

Latent Logic acquired by Waymo. Congratulations to the team!

Read more

MiroBio launches with £27m Series A!

Read more

Ten tools every developer should know in 2018 [Diffblue]

Read more

Genomics raises £25m as it announces deal with US pharma giant

Read more

10 outstanding start-ups from Oxford to watch

Read more

15 Machine Learning Companies To Watch In Europe

Read more

Navenio raises £9m for its hospital workforce AI platform

Read more

NHS to trial Uber-style location service to match up patients, porters and equipment

Read more

Updates

Today @PepGenTx released its second quarter 2022 financial results and a corporate update, including many noteworthy highlights.

Read the full release ⬇

https://bit.ly/3dnAsw8

We released 2Q22 financial results and corporate update:
(1) $32.1m royalty payment from commercial sales of Vaxzevria®
(2) Announced positive data from VTP-300 trial
(3) Enrolled 60th patient in VTP-200 trial
(4) Notable upcoming milestones

See: https://bit.ly/3BQ9CH5

Delighted to announce that our portfolio company
@Miro_Bio is to be acquired by @GileadSciences for approximately $405 million.

Read our full press release to learn more ⬇

https://bit.ly/3zzzJ2i

Stay up to date

Get the latest on cutting edge developments from our enterprises straight to your inbox